1 North Waukegan Road
AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook or LinkedIn.
Stock Symbol: ABBV
Stock Exchange: NYSE
People. Passion. Possibilities. Those three simple words mean everything at AbbVie, where patients always come first. So do cutting-edge science and innovation, which fuel our expanding pipeline as we take on the world's toughest health challenges in oncology, immunology, liver disease, women's health and beyond. Together, we strive to make a difference for patients around the world. For more visit: www.abbvie.com.
772 articles with AbbVie
AbbVie announced today a global resolution of all intellectual property-related litigation with Sandoz over its proposed biosimilar adalimumab product.
Nobel Prizes Underscore Benefits of Research, but Also Highlight ‘Worst Instincts’ of Industry: R...
10/9/2018In a report, Bloomberg said that pharma’s “efforts to maximize (financial) gains” has led to the coloring of R&D decisions and creating barriers to the entry of competing medications that can add costs to the health care system.
AbbVie to Present New Data for Upadacitinib and HUMIRA® (adalimumab) at the 2018 ACR/ARHP Annual Meeting
- Oral presentations include three of the five pivotal studies from AbbVie's SELECT Phase 3 program to support regulatory submission for investigational upadacitinib in patients with moderate to severe rheumatoid arthritis
With cell and gene expertise in high demand, industry innovator will help expand the leading cloud-based software "platform of record"...
10/3/2018The 2018 Nobel Prize in chemistry was awarded to Frances H. Arnold, George P. Smith and Gregory P. Winter for research in utilizing evolutionary principles to create proteins.
Despite winning regulatory approval for a copycat version of Copaxone earlier this year, Cambridge, Mass.-based Momenta Pharmaceuticals has completed a strategic review that includes slashing its staff by 50 percent as the company focuses its resources on two biosimilar candidates in its pipeline.
Swiss-based Roche announced it is buying UK-based Tusk Therapeutics in a deal that could hit $758 million (U.S.).
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against AbbVie Inc. (ABBV) & Lead Plaintiff Deadline - November 20, 2018
Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against AbbVie Inc. and certain of its officers, on behalf of shareholders who purchased or otherwise acquired AbbVie securities between October 25, 2013 and September 18, 2018, both dates inclusive
9/25/2018Shares of Verastem closed out Monday trading on a positive note and continues to climb in the premarket following the greenlight for leukemia drug Copiktra, an inhibitor of phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma.
AbbVie Class Action: Bernstein Liebhard LLP Announces That A Securities Class Action Lawsuit Has Been Filed Against AbbVie Inc. - ABBV
Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of AbbVie Inc.
9/21/2018AbbVie, a research-based global biopharmaceutical company, today announced a donation of $5 million to Family Reach to support the organization’s efforts to alleviate the financial burden of cancer on pediatric patients and families across the United States.
AbbVie Receives Positive CHMP Opinion for a Novel, Chemotherapy-free Combination of VENCLYXTO® (venetoclax tablets) with Rituximab as a Treatment with a Fixed Duration for Patients with Chronic Lymphocytic Leukemia
If approved by the European Commission (EC), VENCLYXTO® plus rituximab would be the first chemotherapy-free combination regimen with a fixed duration of treatment for patients with chronic lymphocytic leukemia who have received at least one prior therapy.
AbbVie Announces $5 Million Donation to Family Reach to Support Children Battling Cancer and Their Families 1
This gift, the largest contribution ever received by Family Reach, will provide critical financial services, support programs and educational resources to families across the United States struggling with the financial burden of a child's cancer diagnosis
Following AbbVie Lawsuit, Government Scrutinizes Industry-Provided Drug Educational Support Services
9/21/2018A federal investigation is underway into whether or not the nursing and other medical services provided by some pharmaceutical companies to doctor’s offices actually violate the law due to serving an illegal commercial service.
Illinois-based AbbVie is under fire from California’s Insurance Commissioner over allegations of a kickback scheme to support sales of blockbuster rheumatoid arthritis treatment Humira in the state.
Kaplan Fox & Kilsheimer LLP has been investigating claims on behalf of investors of AbbVie Inc.
Friday, November 2 2018, AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time
AbbVie Presents Upadacitinib Longer-Term (32-Week) and Patient-Reported Outcomes Data from Phase 2b Atopic Dermatitis Study at 27th European Academy of Dermatology and Venereology (EADV) Congress
Across all doses, a significantly greater proportion of patients who remained on upadacitinib showed continuous improvements in skin lesions and pruritus (itch) at week 32 compared to patients re-randomized to placebo
AbbVie Announces Patient-Reported Outcomes Data from Three Pivotal Phase 3 Studies of Risankizumab, Showing Significant Improvements in Health-Related Quality of Life for Patients with Psoriasis
Significantly more patients treated with risankizumab self-reported a Dermatology Life Quality Index score of 0 or 1 compared with HUMIRA® (adalimumab)-treated patients
Belgium-based Galapagos NV snagged $300 million following its U.S. public offering of new ordinary shares in the form of American Depositary Shares.